nodes	percent_of_prediction	percent_of_DWPC	metapath
Modafinil—CYP1A2—Carmustine—lymphatic system cancer	0.148	0.208	CbGbCtD
Modafinil—CYP3A5—Teniposide—lymphatic system cancer	0.134	0.188	CbGbCtD
Modafinil—CYP2C19—Teniposide—lymphatic system cancer	0.108	0.152	CbGbCtD
Modafinil—CYP2C9—Teniposide—lymphatic system cancer	0.0898	0.126	CbGbCtD
Modafinil—CYP3A5—Vincristine—lymphatic system cancer	0.0645	0.0906	CbGbCtD
Modafinil—CYP3A4—Cytarabine—lymphatic system cancer	0.053	0.0745	CbGbCtD
Modafinil—CYP3A4—Teniposide—lymphatic system cancer	0.0522	0.0734	CbGbCtD
Modafinil—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0365	0.0513	CbGbCtD
Modafinil—CYP3A4—Vincristine—lymphatic system cancer	0.0251	0.0353	CbGbCtD
Modafinil—Cardiac disorder—Vincristine—lymphatic system cancer	0.000619	0.00215	CcSEcCtD
Modafinil—Body temperature increased—Fludarabine—lymphatic system cancer	0.000613	0.00213	CcSEcCtD
Modafinil—Mental disorder—Carmustine—lymphatic system cancer	0.000612	0.00212	CcSEcCtD
Modafinil—Malnutrition—Carmustine—lymphatic system cancer	0.000608	0.00211	CcSEcCtD
Modafinil—Cough—Bleomycin—lymphatic system cancer	0.000608	0.00211	CcSEcCtD
Modafinil—Angiopathy—Vincristine—lymphatic system cancer	0.000605	0.0021	CcSEcCtD
Modafinil—Diarrhoea—Teniposide—lymphatic system cancer	0.000604	0.00209	CcSEcCtD
Modafinil—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000601	0.00209	CcSEcCtD
Modafinil—Myalgia—Bleomycin—lymphatic system cancer	0.000593	0.00206	CcSEcCtD
Modafinil—Chest pain—Bleomycin—lymphatic system cancer	0.000593	0.00206	CcSEcCtD
Modafinil—Back pain—Carmustine—lymphatic system cancer	0.000588	0.00204	CcSEcCtD
Modafinil—Discomfort—Bleomycin—lymphatic system cancer	0.000586	0.00203	CcSEcCtD
Modafinil—Mental disorder—Vincristine—lymphatic system cancer	0.000584	0.00203	CcSEcCtD
Modafinil—Chills—Mitoxantrone—lymphatic system cancer	0.000583	0.00202	CcSEcCtD
Modafinil—Urine output increased—Methotrexate—lymphatic system cancer	0.000583	0.00202	CcSEcCtD
Modafinil—Ecchymosis—Methotrexate—lymphatic system cancer	0.000583	0.00202	CcSEcCtD
Modafinil—Bladder pain—Methotrexate—lymphatic system cancer	0.000583	0.00202	CcSEcCtD
Modafinil—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000583	0.00202	CcSEcCtD
Modafinil—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00058	0.00201	CcSEcCtD
Modafinil—Confusional state—Bleomycin—lymphatic system cancer	0.000573	0.00199	CcSEcCtD
Modafinil—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000571	0.00198	CcSEcCtD
Modafinil—Tremor—Carmustine—lymphatic system cancer	0.00057	0.00198	CcSEcCtD
Modafinil—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000569	0.00197	CcSEcCtD
Modafinil—Oedema—Bleomycin—lymphatic system cancer	0.000569	0.00197	CcSEcCtD
Modafinil—Infection—Bleomycin—lymphatic system cancer	0.000565	0.00196	CcSEcCtD
Modafinil—Anaemia—Carmustine—lymphatic system cancer	0.000562	0.00195	CcSEcCtD
Modafinil—Back pain—Vincristine—lymphatic system cancer	0.000562	0.00195	CcSEcCtD
Modafinil—Vomiting—Teniposide—lymphatic system cancer	0.000561	0.00195	CcSEcCtD
Modafinil—Agitation—Carmustine—lymphatic system cancer	0.000559	0.00194	CcSEcCtD
Modafinil—Asthenia—Fludarabine—lymphatic system cancer	0.000557	0.00193	CcSEcCtD
Modafinil—Rash—Teniposide—lymphatic system cancer	0.000556	0.00193	CcSEcCtD
Modafinil—Dermatitis—Teniposide—lymphatic system cancer	0.000556	0.00193	CcSEcCtD
Modafinil—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000554	0.00192	CcSEcCtD
Modafinil—Headache—Teniposide—lymphatic system cancer	0.000553	0.00192	CcSEcCtD
Modafinil—Pruritus—Fludarabine—lymphatic system cancer	0.000549	0.0019	CcSEcCtD
Modafinil—Back pain—Mitoxantrone—lymphatic system cancer	0.000547	0.0019	CcSEcCtD
Modafinil—Anorexia—Bleomycin—lymphatic system cancer	0.000542	0.00188	CcSEcCtD
Modafinil—Anaemia—Vincristine—lymphatic system cancer	0.000537	0.00186	CcSEcCtD
Modafinil—Agitation—Vincristine—lymphatic system cancer	0.000534	0.00185	CcSEcCtD
Modafinil—Photosensitivity—Methotrexate—lymphatic system cancer	0.000533	0.00185	CcSEcCtD
Modafinil—Polyuria—Methotrexate—lymphatic system cancer	0.000533	0.00185	CcSEcCtD
Modafinil—Hypotension—Bleomycin—lymphatic system cancer	0.000531	0.00184	CcSEcCtD
Modafinil—Diarrhoea—Fludarabine—lymphatic system cancer	0.000531	0.00184	CcSEcCtD
Modafinil—Convulsion—Carmustine—lymphatic system cancer	0.000527	0.00183	CcSEcCtD
Modafinil—Hypertension—Carmustine—lymphatic system cancer	0.000525	0.00182	CcSEcCtD
Modafinil—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000525	0.00182	CcSEcCtD
Modafinil—Nausea—Teniposide—lymphatic system cancer	0.000524	0.00182	CcSEcCtD
Modafinil—Anaemia—Mitoxantrone—lymphatic system cancer	0.000523	0.00181	CcSEcCtD
Modafinil—Vertigo—Vincristine—lymphatic system cancer	0.000522	0.00181	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000518	0.0018	CcSEcCtD
Modafinil—Myalgia—Carmustine—lymphatic system cancer	0.000518	0.0018	CcSEcCtD
Modafinil—Chest pain—Carmustine—lymphatic system cancer	0.000518	0.0018	CcSEcCtD
Modafinil—Anxiety—Carmustine—lymphatic system cancer	0.000516	0.00179	CcSEcCtD
Modafinil—Paraesthesia—Bleomycin—lymphatic system cancer	0.000511	0.00177	CcSEcCtD
Modafinil—Malaise—Mitoxantrone—lymphatic system cancer	0.00051	0.00177	CcSEcCtD
Modafinil—Dyspnoea—Bleomycin—lymphatic system cancer	0.000507	0.00176	CcSEcCtD
Modafinil—Convulsion—Vincristine—lymphatic system cancer	0.000503	0.00174	CcSEcCtD
Modafinil—Hypertension—Vincristine—lymphatic system cancer	0.000501	0.00174	CcSEcCtD
Modafinil—Confusional state—Carmustine—lymphatic system cancer	0.000501	0.00174	CcSEcCtD
Modafinil—Oedema—Carmustine—lymphatic system cancer	0.000496	0.00172	CcSEcCtD
Modafinil—Decreased appetite—Bleomycin—lymphatic system cancer	0.000494	0.00171	CcSEcCtD
Modafinil—Myalgia—Vincristine—lymphatic system cancer	0.000494	0.00171	CcSEcCtD
Modafinil—Cough—Mitoxantrone—lymphatic system cancer	0.000493	0.00171	CcSEcCtD
Modafinil—Infection—Carmustine—lymphatic system cancer	0.000493	0.00171	CcSEcCtD
Modafinil—Vomiting—Fludarabine—lymphatic system cancer	0.000493	0.00171	CcSEcCtD
Modafinil—Convulsion—Mitoxantrone—lymphatic system cancer	0.00049	0.0017	CcSEcCtD
Modafinil—Rash—Fludarabine—lymphatic system cancer	0.000489	0.0017	CcSEcCtD
Modafinil—Dermatitis—Fludarabine—lymphatic system cancer	0.000489	0.00169	CcSEcCtD
Modafinil—Hypertension—Mitoxantrone—lymphatic system cancer	0.000488	0.00169	CcSEcCtD
Modafinil—Pain—Bleomycin—lymphatic system cancer	0.000486	0.00169	CcSEcCtD
Modafinil—Headache—Fludarabine—lymphatic system cancer	0.000486	0.00169	CcSEcCtD
Modafinil—Tachycardia—Carmustine—lymphatic system cancer	0.000485	0.00168	CcSEcCtD
Modafinil—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000483	0.00168	CcSEcCtD
Modafinil—Myalgia—Mitoxantrone—lymphatic system cancer	0.000481	0.00167	CcSEcCtD
Modafinil—Chest pain—Mitoxantrone—lymphatic system cancer	0.000481	0.00167	CcSEcCtD
Modafinil—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000481	0.00167	CcSEcCtD
Modafinil—Anxiety—Mitoxantrone—lymphatic system cancer	0.00048	0.00166	CcSEcCtD
Modafinil—Discomfort—Mitoxantrone—lymphatic system cancer	0.000476	0.00165	CcSEcCtD
Modafinil—Oedema—Vincristine—lymphatic system cancer	0.000474	0.00164	CcSEcCtD
Modafinil—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000474	0.00164	CcSEcCtD
Modafinil—Anorexia—Carmustine—lymphatic system cancer	0.000473	0.00164	CcSEcCtD
Modafinil—Infection—Vincristine—lymphatic system cancer	0.000471	0.00163	CcSEcCtD
Modafinil—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000469	0.00163	CcSEcCtD
Modafinil—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000468	0.00162	CcSEcCtD
Modafinil—Confusional state—Mitoxantrone—lymphatic system cancer	0.000465	0.00161	CcSEcCtD
Modafinil—Nervous system disorder—Vincristine—lymphatic system cancer	0.000465	0.00161	CcSEcCtD
Modafinil—Hypotension—Carmustine—lymphatic system cancer	0.000464	0.00161	CcSEcCtD
Modafinil—Oedema—Mitoxantrone—lymphatic system cancer	0.000462	0.0016	CcSEcCtD
Modafinil—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000462	0.0016	CcSEcCtD
Modafinil—Nausea—Fludarabine—lymphatic system cancer	0.000461	0.0016	CcSEcCtD
Modafinil—Infection—Mitoxantrone—lymphatic system cancer	0.000459	0.00159	CcSEcCtD
Modafinil—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000458	0.00159	CcSEcCtD
Modafinil—Shock—Mitoxantrone—lymphatic system cancer	0.000454	0.00157	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000452	0.00157	CcSEcCtD
Modafinil—Urticaria—Bleomycin—lymphatic system cancer	0.000452	0.00157	CcSEcCtD
Modafinil—Anorexia—Vincristine—lymphatic system cancer	0.000452	0.00157	CcSEcCtD
Modafinil—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00045	0.00156	CcSEcCtD
Modafinil—Body temperature increased—Bleomycin—lymphatic system cancer	0.00045	0.00156	CcSEcCtD
Modafinil—Insomnia—Carmustine—lymphatic system cancer	0.000449	0.00156	CcSEcCtD
Modafinil—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000448	0.00155	CcSEcCtD
Modafinil—Irritability—Methotrexate—lymphatic system cancer	0.000447	0.00155	CcSEcCtD
Modafinil—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000446	0.00155	CcSEcCtD
Modafinil—Paraesthesia—Carmustine—lymphatic system cancer	0.000446	0.00155	CcSEcCtD
Modafinil—Mood swings—Methotrexate—lymphatic system cancer	0.000443	0.00154	CcSEcCtD
Modafinil—Hypotension—Vincristine—lymphatic system cancer	0.000443	0.00154	CcSEcCtD
Modafinil—Dyspnoea—Carmustine—lymphatic system cancer	0.000443	0.00154	CcSEcCtD
Modafinil—Somnolence—Carmustine—lymphatic system cancer	0.000441	0.00153	CcSEcCtD
Modafinil—Anorexia—Mitoxantrone—lymphatic system cancer	0.00044	0.00153	CcSEcCtD
Modafinil—Ataxia—Methotrexate—lymphatic system cancer	0.00044	0.00153	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000432	0.0015	CcSEcCtD
Modafinil—Decreased appetite—Carmustine—lymphatic system cancer	0.000432	0.0015	CcSEcCtD
Modafinil—Hypotension—Mitoxantrone—lymphatic system cancer	0.000431	0.0015	CcSEcCtD
Modafinil—Insomnia—Vincristine—lymphatic system cancer	0.000429	0.00149	CcSEcCtD
Modafinil—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000429	0.00149	CcSEcCtD
Modafinil—Paraesthesia—Vincristine—lymphatic system cancer	0.000426	0.00148	CcSEcCtD
Modafinil—Pain—Carmustine—lymphatic system cancer	0.000425	0.00147	CcSEcCtD
Modafinil—Constipation—Carmustine—lymphatic system cancer	0.000425	0.00147	CcSEcCtD
Modafinil—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000421	0.00146	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00042	0.00146	CcSEcCtD
Modafinil—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000419	0.00145	CcSEcCtD
Modafinil—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000414	0.00144	CcSEcCtD
Modafinil—Decreased appetite—Vincristine—lymphatic system cancer	0.000412	0.00143	CcSEcCtD
Modafinil—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000411	0.00143	CcSEcCtD
Modafinil—Somnolence—Mitoxantrone—lymphatic system cancer	0.00041	0.00142	CcSEcCtD
Modafinil—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000409	0.00142	CcSEcCtD
Modafinil—Feeling abnormal—Carmustine—lymphatic system cancer	0.000409	0.00142	CcSEcCtD
Modafinil—Fatigue—Vincristine—lymphatic system cancer	0.000409	0.00142	CcSEcCtD
Modafinil—Asthenia—Bleomycin—lymphatic system cancer	0.000408	0.00142	CcSEcCtD
Modafinil—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000406	0.00141	CcSEcCtD
Modafinil—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000406	0.00141	CcSEcCtD
Modafinil—Constipation—Vincristine—lymphatic system cancer	0.000405	0.00141	CcSEcCtD
Modafinil—Pain—Vincristine—lymphatic system cancer	0.000405	0.00141	CcSEcCtD
Modafinil—Asthma—Methotrexate—lymphatic system cancer	0.000404	0.0014	CcSEcCtD
Modafinil—Pruritus—Bleomycin—lymphatic system cancer	0.000402	0.0014	CcSEcCtD
Modafinil—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000401	0.00139	CcSEcCtD
Modafinil—Eosinophilia—Methotrexate—lymphatic system cancer	0.0004	0.00139	CcSEcCtD
Modafinil—Fatigue—Mitoxantrone—lymphatic system cancer	0.000398	0.00138	CcSEcCtD
Modafinil—Constipation—Mitoxantrone—lymphatic system cancer	0.000395	0.00137	CcSEcCtD
Modafinil—Pain—Mitoxantrone—lymphatic system cancer	0.000395	0.00137	CcSEcCtD
Modafinil—Abdominal pain—Carmustine—lymphatic system cancer	0.000392	0.00136	CcSEcCtD
Modafinil—Body temperature increased—Carmustine—lymphatic system cancer	0.000392	0.00136	CcSEcCtD
Modafinil—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000388	0.00134	CcSEcCtD
Modafinil—Pancytopenia—Methotrexate—lymphatic system cancer	0.000384	0.00133	CcSEcCtD
Modafinil—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00038	0.00132	CcSEcCtD
Modafinil—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000377	0.00131	CcSEcCtD
Modafinil—Abdominal pain—Vincristine—lymphatic system cancer	0.000375	0.0013	CcSEcCtD
Modafinil—Body temperature increased—Vincristine—lymphatic system cancer	0.000375	0.0013	CcSEcCtD
Modafinil—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000372	0.00129	CcSEcCtD
Modafinil—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000369	0.00128	CcSEcCtD
Modafinil—Urticaria—Mitoxantrone—lymphatic system cancer	0.000367	0.00127	CcSEcCtD
Modafinil—Hypersensitivity—Carmustine—lymphatic system cancer	0.000366	0.00127	CcSEcCtD
Modafinil—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000365	0.00127	CcSEcCtD
Modafinil—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000365	0.00127	CcSEcCtD
Modafinil—Pneumonia—Methotrexate—lymphatic system cancer	0.000363	0.00126	CcSEcCtD
Modafinil—Vomiting—Bleomycin—lymphatic system cancer	0.000362	0.00125	CcSEcCtD
Modafinil—Drowsiness—Methotrexate—lymphatic system cancer	0.000361	0.00125	CcSEcCtD
Modafinil—Depression—Methotrexate—lymphatic system cancer	0.00036	0.00125	CcSEcCtD
Modafinil—Rash—Bleomycin—lymphatic system cancer	0.000359	0.00124	CcSEcCtD
Modafinil—Dermatitis—Bleomycin—lymphatic system cancer	0.000358	0.00124	CcSEcCtD
Modafinil—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000357	0.00124	CcSEcCtD
Modafinil—Asthenia—Carmustine—lymphatic system cancer	0.000356	0.00124	CcSEcCtD
Modafinil—Stomatitis—Methotrexate—lymphatic system cancer	0.000351	0.00122	CcSEcCtD
Modafinil—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00035	0.00122	CcSEcCtD
Modafinil—Hypersensitivity—Vincristine—lymphatic system cancer	0.000349	0.00121	CcSEcCtD
Modafinil—Sweating—Methotrexate—lymphatic system cancer	0.000346	0.0012	CcSEcCtD
Modafinil—Haematuria—Methotrexate—lymphatic system cancer	0.000344	0.00119	CcSEcCtD
Modafinil—Epistaxis—Methotrexate—lymphatic system cancer	0.00034	0.00118	CcSEcCtD
Modafinil—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00034	0.00118	CcSEcCtD
Modafinil—Asthenia—Vincristine—lymphatic system cancer	0.00034	0.00118	CcSEcCtD
Modafinil—Diarrhoea—Carmustine—lymphatic system cancer	0.00034	0.00118	CcSEcCtD
Modafinil—Nausea—Bleomycin—lymphatic system cancer	0.000338	0.00117	CcSEcCtD
Modafinil—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000336	0.00117	CcSEcCtD
Modafinil—Asthenia—Mitoxantrone—lymphatic system cancer	0.000331	0.00115	CcSEcCtD
Modafinil—Dizziness—Carmustine—lymphatic system cancer	0.000328	0.00114	CcSEcCtD
Modafinil—Diarrhoea—Vincristine—lymphatic system cancer	0.000324	0.00112	CcSEcCtD
Modafinil—Pharyngitis—Methotrexate—lymphatic system cancer	0.000321	0.00111	CcSEcCtD
Modafinil—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00032	0.00111	CcSEcCtD
Modafinil—Urethral disorder—Methotrexate—lymphatic system cancer	0.000317	0.0011	CcSEcCtD
Modafinil—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000316	0.0011	CcSEcCtD
Modafinil—Vomiting—Carmustine—lymphatic system cancer	0.000316	0.00109	CcSEcCtD
Modafinil—Dizziness—Vincristine—lymphatic system cancer	0.000313	0.00109	CcSEcCtD
Modafinil—Rash—Carmustine—lymphatic system cancer	0.000313	0.00109	CcSEcCtD
Modafinil—Dermatitis—Carmustine—lymphatic system cancer	0.000313	0.00108	CcSEcCtD
Modafinil—Visual impairment—Methotrexate—lymphatic system cancer	0.000312	0.00108	CcSEcCtD
Modafinil—Headache—Carmustine—lymphatic system cancer	0.000311	0.00108	CcSEcCtD
Modafinil—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000306	0.00106	CcSEcCtD
Modafinil—Vomiting—Vincristine—lymphatic system cancer	0.000301	0.00105	CcSEcCtD
Modafinil—Cardiac disorder—Methotrexate—lymphatic system cancer	0.0003	0.00104	CcSEcCtD
Modafinil—Rash—Vincristine—lymphatic system cancer	0.000299	0.00104	CcSEcCtD
Modafinil—Dermatitis—Vincristine—lymphatic system cancer	0.000299	0.00104	CcSEcCtD
Modafinil—Headache—Vincristine—lymphatic system cancer	0.000297	0.00103	CcSEcCtD
Modafinil—Nausea—Carmustine—lymphatic system cancer	0.000295	0.00102	CcSEcCtD
Modafinil—Angiopathy—Methotrexate—lymphatic system cancer	0.000294	0.00102	CcSEcCtD
Modafinil—Vomiting—Mitoxantrone—lymphatic system cancer	0.000293	0.00102	CcSEcCtD
Modafinil—Immune system disorder—Methotrexate—lymphatic system cancer	0.000292	0.00101	CcSEcCtD
Modafinil—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000292	0.00101	CcSEcCtD
Modafinil—Rash—Mitoxantrone—lymphatic system cancer	0.000291	0.00101	CcSEcCtD
Modafinil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000291	0.00101	CcSEcCtD
Modafinil—Chills—Methotrexate—lymphatic system cancer	0.00029	0.00101	CcSEcCtD
Modafinil—Headache—Mitoxantrone—lymphatic system cancer	0.000289	0.001	CcSEcCtD
Modafinil—Mental disorder—Methotrexate—lymphatic system cancer	0.000284	0.000983	CcSEcCtD
Modafinil—Malnutrition—Methotrexate—lymphatic system cancer	0.000282	0.000977	CcSEcCtD
Modafinil—Nausea—Vincristine—lymphatic system cancer	0.000281	0.000976	CcSEcCtD
Modafinil—Dysgeusia—Methotrexate—lymphatic system cancer	0.000276	0.000957	CcSEcCtD
Modafinil—Nausea—Mitoxantrone—lymphatic system cancer	0.000274	0.000951	CcSEcCtD
Modafinil—Back pain—Methotrexate—lymphatic system cancer	0.000273	0.000945	CcSEcCtD
Modafinil—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000261	0.000907	CcSEcCtD
Modafinil—Anaemia—Methotrexate—lymphatic system cancer	0.00026	0.000903	CcSEcCtD
Modafinil—Malaise—Methotrexate—lymphatic system cancer	0.000254	0.000881	CcSEcCtD
Modafinil—Vertigo—Methotrexate—lymphatic system cancer	0.000253	0.000878	CcSEcCtD
Modafinil—Cough—Methotrexate—lymphatic system cancer	0.000246	0.000853	CcSEcCtD
Modafinil—Convulsion—Methotrexate—lymphatic system cancer	0.000244	0.000847	CcSEcCtD
Modafinil—Arthralgia—Methotrexate—lymphatic system cancer	0.00024	0.000832	CcSEcCtD
Modafinil—Chest pain—Methotrexate—lymphatic system cancer	0.00024	0.000832	CcSEcCtD
Modafinil—Myalgia—Methotrexate—lymphatic system cancer	0.00024	0.000832	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000238	0.000826	CcSEcCtD
Modafinil—Discomfort—Methotrexate—lymphatic system cancer	0.000237	0.000822	CcSEcCtD
Modafinil—Confusional state—Methotrexate—lymphatic system cancer	0.000232	0.000804	CcSEcCtD
Modafinil—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00023	0.000798	CcSEcCtD
Modafinil—Infection—Methotrexate—lymphatic system cancer	0.000228	0.000792	CcSEcCtD
Modafinil—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000226	0.000782	CcSEcCtD
Modafinil—Skin disorder—Methotrexate—lymphatic system cancer	0.000223	0.000775	CcSEcCtD
Modafinil—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000222	0.000771	CcSEcCtD
Modafinil—Anorexia—Methotrexate—lymphatic system cancer	0.000219	0.00076	CcSEcCtD
Modafinil—Hypotension—Methotrexate—lymphatic system cancer	0.000215	0.000745	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00021	0.000727	CcSEcCtD
Modafinil—Insomnia—Methotrexate—lymphatic system cancer	0.000208	0.000721	CcSEcCtD
Modafinil—Paraesthesia—Methotrexate—lymphatic system cancer	0.000206	0.000716	CcSEcCtD
Modafinil—Dyspnoea—Methotrexate—lymphatic system cancer	0.000205	0.000711	CcSEcCtD
Modafinil—Somnolence—Methotrexate—lymphatic system cancer	0.000204	0.000709	CcSEcCtD
Modafinil—Dyspepsia—Methotrexate—lymphatic system cancer	0.000202	0.000702	CcSEcCtD
Modafinil—Decreased appetite—Methotrexate—lymphatic system cancer	0.0002	0.000693	CcSEcCtD
Modafinil—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000199	0.000689	CcSEcCtD
Modafinil—Fatigue—Methotrexate—lymphatic system cancer	0.000198	0.000688	CcSEcCtD
Modafinil—Pain—Methotrexate—lymphatic system cancer	0.000197	0.000682	CcSEcCtD
Modafinil—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000189	0.000657	CcSEcCtD
Modafinil—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000188	0.000652	CcSEcCtD
Modafinil—Urticaria—Methotrexate—lymphatic system cancer	0.000183	0.000634	CcSEcCtD
Modafinil—Abdominal pain—Methotrexate—lymphatic system cancer	0.000182	0.00063	CcSEcCtD
Modafinil—Body temperature increased—Methotrexate—lymphatic system cancer	0.000182	0.00063	CcSEcCtD
Modafinil—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000169	0.000588	CcSEcCtD
Modafinil—Asthenia—Methotrexate—lymphatic system cancer	0.000165	0.000572	CcSEcCtD
Modafinil—Pruritus—Methotrexate—lymphatic system cancer	0.000163	0.000564	CcSEcCtD
Modafinil—Diarrhoea—Methotrexate—lymphatic system cancer	0.000157	0.000546	CcSEcCtD
Modafinil—Dizziness—Methotrexate—lymphatic system cancer	0.000152	0.000527	CcSEcCtD
Modafinil—Vomiting—Methotrexate—lymphatic system cancer	0.000146	0.000507	CcSEcCtD
Modafinil—Rash—Methotrexate—lymphatic system cancer	0.000145	0.000503	CcSEcCtD
Modafinil—Dermatitis—Methotrexate—lymphatic system cancer	0.000145	0.000502	CcSEcCtD
Modafinil—Headache—Methotrexate—lymphatic system cancer	0.000144	0.0005	CcSEcCtD
Modafinil—Nausea—Methotrexate—lymphatic system cancer	0.000137	0.000474	CcSEcCtD
